226 related articles for article (PubMed ID: 30321504)
41. Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Liu D; Tang H; Li XY; Deng MF; Wei N; Wang X; Zhou YF; Wang DQ; Fu P; Wang JZ; Hébert SS; Chen JG; Lu Y; Zhu LQ
Mol Ther; 2017 Mar; 25(3):752-764. PubMed ID: 28202389
[TBL] [Abstract][Full Text] [Related]
42. Small heat shock proteins Hsp27 or alphaB-crystallin and the protein components of neurofibrillary tangles: tau and neurofilaments.
Björkdahl C; Sjögren MJ; Zhou X; Concha H; Avila J; Winblad B; Pei JJ
J Neurosci Res; 2008 May; 86(6):1343-52. PubMed ID: 18061943
[TBL] [Abstract][Full Text] [Related]
43. Pathological Changes of Tau Related to Alzheimer's Disease.
Chu D; Liu F
ACS Chem Neurosci; 2019 Feb; 10(2):931-944. PubMed ID: 30346708
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer's disease.
Liu DY; Zhang L
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8523-8532. PubMed ID: 31646584
[TBL] [Abstract][Full Text] [Related]
45. CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease.
Shentu YP; Huo Y; Feng XL; Gilbert J; Zhang Q; Liuyang ZY; Wang XL; Wang G; Zhou H; Wang XC; Wang JZ; Lu YM; Westermarck J; Man HY; Liu R
Cell Rep; 2018 Jul; 24(3):713-723. PubMed ID: 30021167
[TBL] [Abstract][Full Text] [Related]
46. "Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.
Rao CV; Asch AS; Carr DJJ; Yamada HY
Aging Cell; 2020 Mar; 19(3):e13109. PubMed ID: 31981470
[TBL] [Abstract][Full Text] [Related]
47. Roles of Id1/HIF-1 and CDK5/HIF-1 in cell cycle reentry induced by amyloid-beta peptide in post-mitotic cortical neuron.
Chao AC; Chen CH; Wu MH; Hou BY; Yang DI
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118628. PubMed ID: 31884068
[TBL] [Abstract][Full Text] [Related]
48. N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid-β oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease.
Kodis EJ; Choi S; Swanson E; Ferreira G; Bloom GS
Alzheimers Dement; 2018 Oct; 14(10):1302-1312. PubMed ID: 30293574
[TBL] [Abstract][Full Text] [Related]
49. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease.
Wang G; Huang Y; Wang LL; Zhang YF; Xu J; Zhou Y; Lourenco GF; Zhang B; Wang Y; Ren RJ; Halliday GM; Chen SD
Sci Rep; 2016 May; 6():26697. PubMed ID: 27221467
[TBL] [Abstract][Full Text] [Related]
51. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain.
Kuhla A; Ludwig SC; Kuhla B; Münch G; Vollmar B
Neurobiol Aging; 2015 Feb; 36(2):753-61. PubMed ID: 25448604
[TBL] [Abstract][Full Text] [Related]
52. JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models.
Ploia C; Antoniou X; Sclip A; Grande V; Cardinetti D; Colombo A; Canu N; Benussi L; Ghidoni R; Forloni G; Borsello T
J Alzheimers Dis; 2011; 26(2):315-29. PubMed ID: 21628793
[TBL] [Abstract][Full Text] [Related]
53. Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease.
Seward ME; Swanson E; Norambuena A; Reimann A; Cochran JN; Li R; Roberson ED; Bloom GS
J Cell Sci; 2013 Mar; 126(Pt 5):1278-86. PubMed ID: 23345405
[TBL] [Abstract][Full Text] [Related]
54. Phosphorylation of MAP 1A regulates hyperphosphorylation of Tau in Alzheimer's disease model.
Cai B; Shao N; Ye T; Zhou P; Si W; Song H; Wang G; Kou J
Neuropathol Appl Neurobiol; 2023 Oct; 49(5):e12934. PubMed ID: 37705167
[TBL] [Abstract][Full Text] [Related]
55. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
[TBL] [Abstract][Full Text] [Related]
56. Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology.
Lopes JP; Blurton-Jones M; Yamasaki TR; Agostinho P; LaFerla FM
J Alzheimers Dis; 2009; 16(3):541-9. PubMed ID: 19276549
[TBL] [Abstract][Full Text] [Related]
57. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
Reddy PH; Oliver DM
Cells; 2019 May; 8(5):. PubMed ID: 31121890
[TBL] [Abstract][Full Text] [Related]
58. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
59. Genipin Attenuates Tau Phosphorylation and Aβ Levels in Cellular Models of Alzheimer's Disease.
Li M; Cai N; Gu L; Yao L; Bi D; Fang W; Lin Z; Wu Y; Xu H; Li H; Hu Z; Xu X
Mol Neurobiol; 2021 Aug; 58(8):4134-4144. PubMed ID: 33948899
[TBL] [Abstract][Full Text] [Related]
60. Role of protein phosphatase 2A in Alzheimer's disease.
Rudrabhatla P; Pant HC
Curr Alzheimer Res; 2011 Sep; 8(6):623-32. PubMed ID: 21605044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
